262 related articles for article (PubMed ID: 30818873)
1. Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer-Just About Ready for Prime-Time?
Hofman P; Badoual C; Henderson F; Berland L; Hamila M; Long-Mira E; Lassalle S; Roussel H; Hofman V; Tartour E; Ilié M
Cancers (Basel); 2019 Feb; 11(3):. PubMed ID: 30818873
[TBL] [Abstract][Full Text] [Related]
2. Immune contexture analysis in immuno-oncology: applications and challenges of multiplex fluorescent immunohistochemistry.
Shakya R; Nguyen TH; Waterhouse N; Khanna R
Clin Transl Immunology; 2020; 9(10):e1183. PubMed ID: 33072322
[TBL] [Abstract][Full Text] [Related]
3. Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.
Ilie M; Beaulande M; Hamila M; Erb G; Hofman V; Hofman P
Lung Cancer; 2018 Oct; 124():90-94. PubMed ID: 30268486
[TBL] [Abstract][Full Text] [Related]
4. Digital analysis of the prostate tumor microenvironment with high-order chromogenic multiplexing.
Rajendran R; Beck RC; Waskasi MM; Kelly BD; Bauer DR
J Pathol Inform; 2024 Dec; 15():100352. PubMed ID: 38186745
[TBL] [Abstract][Full Text] [Related]
5. Overview of Tissue Imaging Methods.
Patel SS; Rodig SJ
Methods Mol Biol; 2020; 2055():455-465. PubMed ID: 31502165
[TBL] [Abstract][Full Text] [Related]
6. Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging.
Locke D; Hoyt CC
Front Mol Biosci; 2023; 10():1051491. PubMed ID: 36845550
[TBL] [Abstract][Full Text] [Related]
7. State-of-the-Art of Profiling Immune Contexture in the Era of Multiplexed Staining and Digital Analysis to Study Paraffin Tumor Tissues.
Parra ER; Francisco-Cruz A; Wistuba II
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30791580
[TBL] [Abstract][Full Text] [Related]
8. The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies.
Sadeghi Rad H; Bazaz SR; Monkman J; Ebrahimi Warkiani M; Rezaei N; O'Byrne K; Kulasinghe A
Clin Transl Immunology; 2020; 9(11):e1215. PubMed ID: 33251010
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
10. In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide.
Remark R; Merghoub T; Grabe N; Litjens G; Damotte D; Wolchok JD; Merad M; Gnjatic S
Sci Immunol; 2016 Jul; 1(1):aaf6925. PubMed ID: 28783673
[TBL] [Abstract][Full Text] [Related]
11. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Syn NL; Yong WP; Goh BC; Lee SC
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
[TBL] [Abstract][Full Text] [Related]
12. [Digitalization and multiplex IHC as predictive biomarkers for novel immune-therapeutics : New challenges for immunohistochemistry].
Zielinski D
Pathologe; 2019 May; 40(3):256-263. PubMed ID: 31089796
[TBL] [Abstract][Full Text] [Related]
13. Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
Hofman V; Lassalle S; Bence C; Long-Mira E; Nahon-Estève S; Heeke S; Lespinet-Fabre V; Butori C; Ilié M; Hofman P
Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29534030
[TBL] [Abstract][Full Text] [Related]
14. Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients.
Mezheyeuski A; Bergsland CH; Backman M; Djureinovic D; Sjöblom T; Bruun J; Micke P
J Pathol; 2018 Apr; 244(4):421-431. PubMed ID: 29282718
[TBL] [Abstract][Full Text] [Related]
15. [Digital pathology in immuno-oncology-current opportunities and challenges : Overview of the analysis of immune cell infiltrates using whole slide imaging].
Grabe N; Roth W; Foersch S
Pathologe; 2018 Nov; 39(6):539-545. PubMed ID: 30350177
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathology of lung cancer: current status and perspectives.
Oberndorfer F; Müllauer L
Curr Opin Oncol; 2018 Mar; 30(2):69-76. PubMed ID: 29251665
[TBL] [Abstract][Full Text] [Related]
17. The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology.
Lin VTG; Yang ES
J Natl Cancer Inst; 2019 Oct; 111(10):1016-1022. PubMed ID: 31165154
[TBL] [Abstract][Full Text] [Related]
18. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
Flynn MJ; Larkin JMG
Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
[TBL] [Abstract][Full Text] [Related]
19. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
20. New tools for pathology: a user's review of a highly multiplexed method for in situ analysis of protein and RNA expression in tissue.
Decalf J; Albert ML; Ziai J
J Pathol; 2019 Apr; 247(5):650-661. PubMed ID: 30570141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
